Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
-Fixed - dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-head study . The fixed dose combination had...
Call for Papers | Symposium of the Silk Road Week from China National Silk Museum
HANGZHOU, China, March 27, 2026 /PRNewswire/ -- To further elaborate on the cultural values of the Silk Road, and to advance the preservation of Silk Road cultural heritage, innovation in museum practices, and research on Silk Road civilizations,...
SMARTIES™ 2026: Where Marketing Excellence Meets Real-World Impact - Thailand, Now Is Your Time to Shine
BANGKOK, March 25, 2026 /PRNewswire/ -- The Marketing + Media Alliance (MMA) proudly announces the opening of entries for the SMARTIES™ Thailand 2026. Thailand is one of the few markets where advertising is treated as entertainment. Thai marketers...
SMARTIES™ 2026: Where Marketing Excellence Meets Real-World Impact - The Philippines is Ready for the Global Stage
MANILA, Philippines, March 25, 2026 /PRNewswire/ -- The Marketing + Media Alliance (MMA) proudly announces the opening of entries for the SMARTIES™ Philippines 2026. The Philippines is one of the world's most socially active digital markets, where...
SMARTIES™ Awards 2026 Call for Entries, Celebrating Marketing That Drives Real Business Impact
SINGAPORE, March 24, 2026 /PRNewswire/ -- The Marketing + Media Alliance (MMA) proudly announces the opening of entries for the 2026 SMARTIES™ Awards, the premier marketing awards program that honors trailblazing brands, agencies, and marketers...
Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models
- In a head-to-head cyclic adenosine monophosphate (cAMP) activation assay vs. eloralintide, oral small molecule amylin receptor agonist ASC39 demonstrated similar selectivity and potency to that of eloralintide. EC 50 for human amylin 1 receptor...
Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing in humans. - ASC37's average in vitro activity was...
INVITATION FOR EXPRESSION OF INTEREST - For Divestiture of 'Canwill Holdings (Pvt) Ltd'
COLOMBO, Sri Lanka, Jan. 20, 2026 /PRNewswire/ -- The Government of Sri Lanka (GoSL) intends to divest the 100% shareholding in Canwill, the parent company to Sinolanka Hotels & Spa (Pvt) Ltd (Sinolanka) and Helanco Hotels & Spa (Pvt) Ltd...
Ericsson announces proposed headcount reduction in Sweden
STOCKHOLM, Jan. 15, 2026 /PRNewswire/ -- Ericsson (NASDAQ: ERIC) today announces proposed staff reductions in Sweden as part of measures aimed at ensuring the Company's competitive position. The proposed staff reduction is part of global initiatives...
Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus
- UCSD's Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses 'Xafty' as "The weapon to end the virus war." - Announces "One Drug, Two Tracks" strategy: Targeting Dengue in Vietnam and Respiratory Viruses (Flu, COVID, RSV) in the U.S. with the...